Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai MedicilonSHSE:688202 -1.12%69 OCF Yield % is 0.89 as of Jul. 14, 2026, which is 3% below its 10-year median of 0.92. GuruFocus rates SHSE:688202 with a GF Score™ of 69/100 and a GF Value™ of ¥45.80 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,410 Biotechnology companies, Shanghai Medicilon ranks better than 81.35% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Shanghai Medicilon OCF Yield % Related Terms
Shanghai Medicilon OCF Yield % Historical Data
* Premium members only.
The historical data trend for Shanghai Medicilon's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688202 vs VRTX, REGN, ALNY: OCF Yield % Comparison
For the Biotechnology subindustry, Shanghai Medicilon's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Medicilon OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Medicilon's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Shanghai Medicilon's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Medicilon (SHSE:688202) has a OCF Yield % of 0.89 as of Jul. 14, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Shanghai Medicilon and its competitors. This is near median its historical median of 0.92. According to the industry distribution chart, Shanghai Medicilon ranks #263 out of 1410 companies in the Biotechnology industry, placing it in the top 18.7%.
Is Shanghai Medicilon's OCF Yield % too high?
Shanghai Medicilon's current OCF Yield % of 0.89 is near median its 10-year median of 0.92. Based on the distribution chart, Shanghai Medicilon ranks #263 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Medicilon has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Medicilon's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Medicilon ranks #263 out of 1410 companies for OCF Yield %. This places Shanghai Medicilon in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Shanghai Medicilon and its competitors. Shanghai Medicilon's current OCF Yield % is 0.89, which is near median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Medicilon stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Medicilon (SHSE:688202) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥45.80, compared to a current price of ¥83.20 — trading 81.7% above its estimated fair value. The current OCF Yield % is 0.89, which is near median its 10-year median of 0.92. Shanghai Medicilon's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Shanghai Medicilon (SHSE:688202), the current OCF Yield % is 0.89 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Medicilon (SHSE:688202) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Medicilon stock appears to be overvalued.
The current stock price of ¥83.20 is trading 81.7% above its estimated GF Value™ of ¥45.80.
GuruFocus considers Shanghai Medicilon to be Significantly Overvalued.
Key valuation signals for SHSE:688202:
OCF Yield %: 0.89 (near median its 10-year median of 0.92)
GF Value™: ¥45.80 vs. price of ¥83.20 (81.7% above fair value)
No single metric tells the full story. See the SHSE:688202 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.
69GF Score
Get the complete analysis for SHSE:688202
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688202 has been successfully added to your 
